NanoEngineer,
Agree with all you said. I'll add that I believe they are quite aware that a deal is needed sooner rather than later and I think the B-OM results will expedite a deal(s). The agreement with Evonik has been made which should bring some credibility to the company. Evonik is a big name in the industry.
I've got to think, based on the results, that the doctors who took part in the study must be talking. From the ipix 4/16/18 pr: "Positive OM assessment endpoints are additionally supported by zero (0) of the patients in the Brilacidin-OM group having unplanned office visits, ED visits, or hospital admissions due to OM, compared to four (4) patients in the placebo group."
Zero unplanned visits compared to the 12/5/17 article in BayStreet: "For cancer patients receiving a standard regimen of chemotherapy, it’s estimated that 40 percent will develop OM. The Centers for Disease Control and Prevention estimates that about 650,000 cancer patients receive chemotherapy in an outpatient setting each year in the U.S. Generally speaking, there is a consensus that about 500,000 cases of OM occur in the U.S. annually right now.
Add in the economic burden and the market opportunity to address OM becomes even more clear. Estimates from a study published on PubMed pegged the supportive care costs of severe chemo-radiation-induced OM at $17,244 more than similar cancer patients without severe OM. It’s worth noting those figures were from nearly a decade ago and likely higher now. Not to say that every patient develops severe OM or tips the high-end of the supportive costs, but the metrics of 500,000 cases and $17,244 more per patient equates to a potential annual savings around $8.6 billion." That just the U.S- savings of ~8.6B because of unintended supportative care(estimate was ~10 years ago).
Granted, the BayStreet article covers all chemo induced OM whereas ipix tested OM in head and neck cancer patients. I'll it work as efficiently in all forms of OM.
Those results should get peopole's attention. IPIX should contact the Boston Globe to write a story of interest.
